Kairos Pharma (NYSEAMERICAN:KAPA) Issues Earnings Results

Kairos Pharma (NYSEAMERICAN:KAPA) released its quarterly earnings results on Tuesday. The company reported ($0.07) earnings per share for the quarter, FiscalAI reports.

Kairos Pharma Trading Down 1.3%

Shares of KAPA stock traded down $0.01 on Thursday, reaching $0.57. The company’s stock had a trading volume of 25,261 shares, compared to its average volume of 516,670. The stock’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.84. Kairos Pharma has a 1 year low of $0.40 and a 1 year high of $2.11. The company has a market capitalization of $11.89 million, a price-to-earnings ratio of -1.90 and a beta of 1.96.

Institutional Investors Weigh In On Kairos Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in KAPA. FNY Investment Advisers LLC bought a new stake in Kairos Pharma in the third quarter worth about $27,000. XTX Topco Ltd raised its holdings in shares of Kairos Pharma by 290.8% in the fourth quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock worth $34,000 after buying an additional 36,086 shares during the period. Finally, Two Sigma Investments LP bought a new stake in shares of Kairos Pharma during the 3rd quarter worth approximately $54,000.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.